Source: PharmaLetter | October 18, 2016
In our weekly expert view piece, Rohit Malpani, director of policy and analysis for Mèdecins Sans Frontiéres Access Campaign, discusses the UN Secretary General’s High-Level Panel report on Access to Medicines and looks at the responsibilities it places on industry.
During the UN General Assembly in New York last month, the UN Secretary General’s High-Level Panel on Access to Medicines released its much-anticipated report, containing recommendations for governments and the pharmaceutical industry on how to enable better access to medicines and vaccines and how to ensure medical research and development (R&D) addresses unmet priority health needs. Continue reading
Source: PTI | October 18, 2016
Kerala government has opposed Centre’s move to sign the Regional Comprehensive Economic Partnership (RCEP) agreement, saying it would further worsen the crisis in the state’s cash crops sector.
By By Mehk Chakraborty, Media India| October 14, 2016
Médecins Sans Frontières (MSF) or Doctors Without Borders have called the negotiating countries for upcoming Regional Comprehensive Economic Partnership (RCEP) trade agreement to reject terms that could potentially harm access to medicines for its citizens. Continue reading
Press Release: AFTINET | October 18, 2016
Public health and community groups condemn stronger medicine monopolies as RCEP mega trade deal talks continue this week.
Ninety-four public health and other community groups from 12 countries have condemned proposals for the inclusion of stronger medicine monopolies in the Regional Comprehensive Economic Partnership (RCEP) as secret negotiations continue this week in China. Continue reading
By The Hindu BusinessLine | October 14, 2016
The 15th round of meetings on the Regional Comprehensive Economic Partnership (RCEP) trade agreement begins in China on October 17. RCEP is a free trade agreement under negotiation between the ten-member Association of South East Asian and six countries, which have established trade agreements with ASEAN: Australia, India, New Zealand, China, Japan and Korea. A key niggling point at RCEP is the inclusion of intellectual property in trade agreements. And such provisions would work against access to affordable generic drugs exported from India, say civil society groups. The fortnight is also expected to see a development on the use of plastic or glass as packaging material for medicines. The case is scheduled to come up at the National Green Tribunal.
By Anton Hermansyah, The Jakarta Post | October 17, 2016
An activist group is calling on the government to not ratify the ASEAN Regional Comprehensive Economic Partnership (RCEP) clause on International Union for the Protection of New Varieties of Plants (UPOV) 1991, saying that it will increase global corporations’ monopolistic control over small farmers. Continue reading
By Mike Palmedo, www.infojustice.org | October 17, 2016
India is often called the “pharmacy of the developing world” because its pharmaceutical firms provide a large portion of the generic drugs consumed in the South. However, Northern countries are increasingly importing Indian drugs as well, as high prices have led to greater generic uptake. Continue reading